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GENERAL INTRODUCTION 
Bovine viral diarrhea virus (BVDV) causes several disease processes that are of 
economic importance in cattle. The virus is found in most cattle populations throughout the 
world. Serological surveys indicate that 60 to 90 percent of cattle over one year of age have 
neutralizing antibodies against BVDV. Viral infection of seronegative, immunocompetent, 
nonpregnant cattle usually results in subclinical disease, followed by the development of 
viral-neutralizing antibodies. However, infection may also cause reproductive failure, and 
immunosuppression, and is often associated with respiratoiy disease complex of calves in 
feedlots. Infection of pregnant cattle may result in fetal resorption, abortion, fetal 
mummification, congenital defects, congenital persistent infection and congenital viral 
specific immunotolerance. A final outcome of congenital persistent infection may be either 
mucosal disease or chronic BVD, both of which have a high rate of mortality. 
BVDV in the United States was first described by Olafson et al. in 1946 (Olafson et 
al., 1946; Olafson and Rickard, 1947). The bovine viral diarrhea virus agent was first 
isolated from a bovine cell culture by Lee and Gillespie (1957). Originally, it was thought 
that two similar but different diseases, bovine viral diarrhea (BVD) and mucosal disease 
(MD), occurred in cattle. Bovine viral diarrhea is a disease of high morbidity (80-100%) 
and low mortality (0-20%), whereas mucosal disease has a low morbidity (5-10%) and high 
mortality (90-100%). In the early 1960's, Pritchard et al., 1961, demonstrated that both 
diseases were caused by BVDV. 
Studies of the molecular characteristics, as well as proteins coded by the virus, have 
been hampered by the low titers to which BVDV grows in cell culture. Once propagated, the 
virus is difficult to purify from host cell contaminants. Reports describing BVDV 
polypeptides have been published (Purchio et al., 1984; Donis and Dubovi, 1987a,b), but a 
concise and detailed topographic map of relevant neutralizing epitopes has not been reported. 
2 
This may be due to the difficulties in purifying virion proteins and the subsequent lack of 
reliable solid-phase assays. However, a topographic map, based on available monoclonal 
antibodies, would provide important information about the position of neutralizing epitopes 
on the viral proteins. Used in conjunction with recent advances in sequencing of the genome 
of BVDV, an epitopic map could lead to the development of vaccines with greater efficacy. 
Also, the distribution of specific epitopes within various isolates of BVDV may give a clearer 
understanding of how the antigenic nature of the virus is altered by mutation. 
Explanation of Dissertation Format 
The objectives of the research presented here were to: i) develop a solid-phase assay 
that could be used to detect reactions of antibody with BVDV antigen, ii) generate a 
topographic map of neutralizing epitopes on the envelope glycoprotein of BVDV, iii) develop 
a rapid and efficient method for extraction of BVDV antigen, and iv) use the extracted BVDV 
antigen in a modified solid-phase assay to detect antibody against BVDV in fetal bovine sera. 
This dissertation is presented in the alternate format including two manuscripts 
prepared for submission to scientific journals. The first manuscript was written for 
submission to Archives of Virology. The second manuscript was written for submission to 
the Journal of Virological Methods. 
The format used for literature cited is that of the Journal of General Virology. A 
literature review precedes the first manuscript. A general summary and discussion follows 
the last manuscript. The literature cited within each manuscript appears following that 
manuscript Literature cited within the general introduction, literature review, and general 
summary and discussion is presented at the end of the dissertation. 
3 
The Ph D candidate Robert C. Unfer, was the primary investigator for each of these 
studies. 
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REVIEW OF LITERATURE 
Bovine Viral Diarrhea Virus 
Bovine Viral Diarrhea Virus (BVDV) is the type species of the genus Pestivirus. 
Other members of this genus include hog cholera virus (HCV) of swine, and border disease 
virus (BDV) of sheep. BVDV commonly infects cattle, but also may infect sheep, goats, 
swine, and wild ruminants. While currently classified as non-arthropod-bome members of 
the Togaviridae family (Mathews, 1982; Westaway et al., 1985), accumulating evidence 
demonstrating fundamental differences at the molecular level of pestiviruses may dictate their 
reclassification. 
Two biotypes of BVDV exist, cytopathic (CP) and noncytopathic (NCP). These are 
distinguished on the basis of microscopically observable changes (vacuolation and cell 
rounding) in cell culture monolayers. BVDV was first propagated in cell culture by Lee and 
Gillespie (1957) using bovine skin-muscle cells. Inidal isolates of BVDV were noncyto­
pathic in cell culture. The presence of vims was detected by inoculation of serologically 
negative calves. Cytopathic BVDV were originally isolated from tissues of cattle by 
Underdahl et al. (1957) and Gillespie et al. (1960). Immunological cross-reactivity between 
both biotypes of virus was demonstrated by several investigators (Gillespie et al., 1961; 
Pritchard, 1963; Thomson and Savan, 1963). Both CP and NCP isolates induce disease in 
cattle (Jubb and Kennedy, 1985). 
Olafson et al. (1946) originally described an acute, infectious, and highly contagious 
disease of cattle, characterized by gastroenteritis witii severe diarrhea, and a low rate of 
mortality. Olafson and Rickard (1947) termed the syndrome "virus diarrhea" of cattle. The 
viral etiology of the disease was proven by reproduction of the disease in calves by using 
filtrates of serum from other infected calves (Baker, 1954). In nature, horizontal 
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transmission occurs by inhalation or ingestion of viral particles (Blood et al., 1983). Sources 
of BVDV are clinically ill or apparently healthy, persistently infected cattle that shed virus in 
infected saliva, oculonasal discharge, urine, and feces (Malmquist, 1968; Heuschele, 1978; 
Coria and McClurkin, 1978; Steck, 1980; Kahrs, 1981; McClurkin et al., 1985). Virus may 
be present in semen, uterine secretion, amniotic fluid, and placental tissue (Coria and 
McClurkin, 1978; Stober, 1984). In addition, vertical transmission from dam to fetus can 
occur transplacentally (Romvary, 1965; Malmquist, 1968; Kendrick, 1971). Indirect 
transmission occurs via fomites, such as feed and equipment (Kahrs, 1981; Stober, 1984). 
Açutg Infection 
Serologic surveys indicate that 60 to 90 percent of all cattle have serum-neutralizing 
antibodies to BVDV. Clinical disease is seldom observed, indicating that most infections 
with BVDV are subclinical (Harkness et al., 1978; Stott et al., 1980; Bolin et al., 1985d). 
Transient pyrexia, leukopenia (Pritchard et al., 1956; Carlson et al., 1957), and viremia 
(Tyler and Ramsey, 1965) appear four to seven days postinfection, and can last for up to 
fifteen days (Nuttall et al., 1980; Bolin et al., 1985b). Transient diarrhea may develop in 
some cattie. Dairy cows often experience a decrease in milk yield. Usually, neutralizing 
antibodies specific for the virus are produced within two to three weeks after infection and 
the virus is cleared from tiie body. Despite apparent life-long antibody production, some 
cattle may be susceptible to reinfection (Brownlie et al., 1987). 
Although most BVDV infections of cattle result in subclinical or mild disease, the 
immunosuppressive effects associated with infection may enhance the pathogenicity of other 
agents, such as coronavirus, infectious bovine rhinotraceitis virus (IBR), parainfluenza virus 
type 3 (PI 3), rotavirus, Actinomvces pvogenes. coccidia, Pasteurella spp., and Salmonella 
spp. (Reggiardo and Kaeberle, 1981; Yates, 1982; Potgeiter et al., 1984; Edwards et al.. 
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1986; Baker, 1987). Suppression of interferon production (Diderholm and Dinter, 1966), 
decreased lymphocyte numbers (Bolin et al., 1985c), impaired lymphocyte function 
(Muscoplat et al., 1973a,b; Johnson and Muscoplat, 1973; Roth et al., 1986), monocyte 
chemotaxis (Johnson and Muscoplat, 1973; Ketelson et al., 1979), humoral antibody 
production (Atluro et al., 1979), as well as polymorphonuclear leukocyte function (Roth et 
al., 1981) have been demonstrated. 
Bovine respiratory disease, which is considered to have a multi-component etiology 
(Lillie, 1974), is often associated with BVDV infection (Woods et al., 1973). Clinical 
manifestations of BVDV infection of the respiratory tract have been described by several 
investigators (Pritchard et al., 1954; Avellini et al., 1968) and include: different types of 
coughs, an increased respiratory rate, and nasal discharge. BVDV is often isolated with 
other viruses during outbreaks of respiratory disease. Dual infections of BVDV with PI-3 
virus (Nystedt, 1960), and IBR virus (Gratzek et al., 1966) have been reported. Tyler and 
Ramsey ( 1965) and Potgeiter et al. ( 1984) reported that the combination of BVDV and IBR 
virus caused a more serious infection than either virus alone. The immuno-suppressive 
effects of BVDV infection may contribute to the pathogenesis of bovine respiratory disease 
(Malmquist, 1968). 
Congenital Infections 
Transplacental infection is a frequent sequela to acute infection in the pregnant dam 
(Binkhorst et al., 1983; Roeder and Harkness, 1986). The gestational age of the fetus 
determines the outcome of infection (Orban et al., 1983; Liess et al., 1984; McClurkin et al., 
1984). For example, fetal infection with either cytopathic or noncytopathic BVDV between 
50 and 100 days of gestation may result in fetal resorption, abortion, and mummification 
(Casaro et al., 1971; Kendrick, 1971; Done et al., 1980). Infection from 100 to 180 days of 
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gestation may lead to congenital malformations of newborn calves, cerebellar hypoplasia 
(Brown et al., 1974), ocular abnormalities (Brownlie et al., 1975), or the birth of weak, 
undersized calves (Done et al., 1980 ). Infections during the later stages of pregnancy (after 
180 days of gestation) may result in the birth of normal calves with antibodies against 
BVDV. 
Persistent Infection 
Fetal infection with a noncytopathic viral isolate before 125 days of gestation may 
result in a congenital, persistent infection with BVDV that is lifelong. Persistently infected 
cattle are immunotolerant to the virus that infects them, but respond immunologically to a 
heterologous BVDV (Steck et al., 1980; Liess et al., 1983; Bolin et al., 1985b). Persistently 
infected calves may be smaller than healthy calves at birth and have a slower rate of growth. 
The death rate of persistently infected calves may be as high as 50% in the first year of life. 
Persistently infected calves may be predisposed to infection by microorganisms leading to 
enteritis and pneumonia (Barber et al., 1985). In addition, persistently infected cattle are at 
risk for development of mucosal disease. Persistentiy infected cattle constantly shed BVDV 
into the environment and are a source of virus for transmission to susceptible animals 
(Roeder and Harkness, 1986). Persistent infection appears to be an important mechanism by 
which tfie virus is maintained in the catde population. Offspring of persistentiy infected 
females are tiiemselves persistentiy infected (McCIurkin et al., 1979; Littiejohns and Walker, 
1985). 
The prevalence of persistently infected catde is not precisely known. Up to 1.7% of 
cattie in the United States may be carriers (Bolin et al., 1985d). Lower rates have been 
reported elsewhere in the world (Meyling, 1984; Howard et al., 1986; Peters et al., 1987). 
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Venereal Transmission 
Semen fmm acutely-infected bulls may be contaminated with infectious virus 
(Whitmore et al., 1978). Semen from persistently-infected bulls contains virus infective to 
susceptible cows (Coria and McClurkin, 1978; McClurkin et al., 1979; Barlow et al., 1986). 
Infected semen may be characterized by decreased motility and morphologic abnormalities 
(McClurkin et al., 1979; Revell et al., 1988). Seronegative dams demonstrate a reduced 
conception rate until they develop a specific immune response to BVDV. Early embryo loss 
and repeat breeding difficulties may result from venereal infection (McClurkin et al., 1979). 
Mucosal Piseasg 
Ramsey and Chivers (1953) and Ramsey (1954) reported a disease syndrome which 
was termed "mucosal disease" (MD) due to lesions found on mucosal membranes. Mucosal 
disease differed from virus diarrhea described by Pritchard et ai. (1956) in severity of clinical 
signs. Usually, less than five percent of a herd presents the symptoms of mucosal disease, 
but up to one hundred percent of affected cattle may die. Gillespie and Baker (1959) 
demonstrated that viral isolates from both "virus dianiiea" and mucosal disease conferred 
mutual protection. Gillespie et al. (1961) demonstrated that the virus isolated from cattle tliat 
had "virus diarrhea" and mucosal disease were antigenically related. 
Mucosal disease is a sporadic form of BVDV infection of cattle. The disease 
develops following superinfection of persistently infected cattie with a cytopathic isolate of 
BVDV (Brownlie et al., 1984; Bolin et al., 1985a). Only certain complementary pairs of 
cytopathic and noncytopathic BVDV induce mucosal disease (Bolin et al., 1985b). Clinical 
signs include depression, anorexia, salivation, and elevated temperatures. Cattie often 
develop a profuse and watery diarrhea, containing mucus and blood. Dehydration and loss 
of body weight follows. Lesions observed on postmortem examination include: erosions and 
9 
ulcers of the esophagus, jejunum, ileum and rectum; elongated ulcers over ileal Peyer's 
patches, and epithelial necrosis and sloughing in the alimentary tract. 
Some cattle develop a chronic wasting disease termed chronic B VD instead of 
mucosal disease. Clinical signs include inappetance, weight loss, progressive emaciation, 
and continual or intermittent diarrhea (Pritchard et ai., 1956; Johnson and Muscoplat, 1973; 
Bolin et al., 1987). Lesions of chronic mucosal disease are less severe than those of acute 
mucosal disease (Muscoplat et al., 1973; Bolin et al., 1987). Cattle with chronic mucosal 
disease have a congenital persistent noncytopathic BVDV infection, but cytopathic BVDV is 
not always isolated (McClurkin et al., 1985; Bolin et al., 1987). Infected cattle may survive 
as long as eighteen months before dying from severe debilitation. 
Serological Relatedness of Pestiviruses 
The serological relatedness of BVDV to HCV was reported by Darbyshire (1960, 
1962), and confirmed by Snowden and French (1968) and Liess et al. (1977). 
Neutralization assays distinguish BVDV from HCV (Sheffy, 1962), but do not distinguish 
between BVDV and BDV (Vantsis et al., 1976; Laude and Guelfi, 1979). The serologic 
cross relatedness of BVDV, and lack of distinct serotypes, is an accepted convention 
(Carbrey, 1988; Moennig et al., 1988; Cay et al., 1989). However, antigenic differences 
demonstrated by cross neutralization tests, using polyclonal sera (Aynaud et al., 1974; 
Neukirch et al., 1980) and monoclonal antibodies (Bolin et al., 1988; Donis et al., 1988; 
Magaret al., 1988; Corapi et al., 1988; Corapi and Dubovi, 1990), indicate variation among 
isolates. 
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Physical-Chemical Characteristics 
BVDV is a small, enveloped, single stranded, positive-sense RNA virus (Diderholm 
and Dinter, 1966; Purchio et al., 1983). The diameter has been estimated to be from 40 - 60 
nm (Kniazeff and Pritchard, 1960; Hermodsson and Dinter, 1962; Hafez et al., 1968; Maess 
and Retzlo, 1970; Horzinek et al., 1971). BVDV replication is not inhibited by 5-iodo-
deoxyuridine (Hermodsson and Dinter, 1962; Ditchfield and Doane, 1964; Castrucci et al., 
1967), but BVDV RNA is sensitive to proflavin and acriflavin (Dinter and Diderholm, 1971; 
Diderholm et al., 1973). The virus is sensitive to ether and chloroform (Hermodsson and 
Dinter, 1962; Gillespie et al., 1963; Castrucci et al., 1967), and is stable at pH 4.0 - 8.0 
(Ditchfield and Doane, 1964). Virus infectivity is greatly reduced by incubation at 56 C for 
one hour. Ultraviolet light and detergents also reduce infectivity (Westaway et al., 1985). 
Estimates of BVDV buoyant density range from 1.09 g/ml (Parks et al., 1972) to 1.15 g/ml 
(Zeegers and Horzinek, 1977; Femelius, 1968). 
Virus particles in electron micrographs appear as pleomorphic, mostly spherical, 
membrane-bound structures (Bielefeldt-Ohmann and Bloch, 1982). The viral core is an 
isometric, electron-dense structure, approximately 20 - 30 nm in diameter (Horzinek et al., 
1971; Chasey and Roeder, 1981; Gray and Nettleton, 1987). Surface projections cannot be 
distinguished on purified virus or virus particles in cells and tissues (Stott et al., 1974; 
Bielefeldt-Ohmann and Bloch, 1982). Surface structures may be lost during concentration 
and purification procedures (Horzinek et al., 1975). Surface subunits, 5 - 8 nm in diameter 
and devoid of hemagglutinating activity have been described (Smith et al., 1970). The 
estimated isoelectric points (pi) of most BVDV proteins are high. Only one BVDV protein, 
p80, has a predicted pi below 7.0 (Collett et al., 1988b). 
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Viral Growth Characteristics 
Viral replication takes place in the cell cytoplasm, closely associated with the 
endoplasmic reticulum. Budding of viral particles into cytoplasmic vesicles, endoplasmic 
reticulum modiHed into tubules (Chasey and Roeder, 1981; Gray and Nettleton, 1987), and 
autophagosomes or golgi networks (Bielefeldt-Ohmann et al., 1988) has been observed. 
Budding of viral particles from the plasma membrane has not been observed. Release of 
viral particles from infected cells occurs either by disintegration of dead cells, or by an 
exocytotic event (Bielefeldt-Ohmann and Bloch, 1982). 
Kinetic growth studies of infected cell cultures indicate that the virus has a lag phase 
that lasts six to eight hours post infection (PI), followed by a log phase of growth lasting 
until twelve hours PI (Nuttall, 1980). A putative cellular receptor for BVDV on the surface 
of cultured bovine cells has been described (Moennig et ai., 1989). A monoclonal antibody 
directed against a bovine cell-surface protein interfered specifically with BVDV infectivity. 
However, this interference of infection was not complete. This finding suggests that BVDV 
entry into bovine cells may be mediated by a specific cell receptor or multiple receptors. 
BVDV Genome 
Molecular characterization of BVDV has been limited by difficulties with propagation 
and purification of the virus. Subgenomic virus-specific RNA species have not been detected 
(Purchio et al., 1983; Renard et al., 1985), distinguishing BVDV from Alphaviruses which 
produce viral genomic (49S) and subgenomic (26S) RNA's in infected cells (Strauss and 
Strauss, 1977). The cloned genomes of two cytopathic BVDV isolates, Osloss and NADL, 
measure approximately 12,5CX) nucleotides in length, corresponding to a molecular mass of 
4.3 X 10^ daltons (Renard et al., 1985; Collett et al., 1988a). Dale et al. (1987) reported the 
cloning of a truncated 1149 nucleotide segment of a third cytopathic viral isolate. Sequence 
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analysis of the larger cloned genomes, using the method of Pustell and Kafatos (1982, 
1984), gave a base composition of A 31.7%, G 25.7%, U 22.2%, C 20.4%. There was a 
74% identity between BVDV-NADL and BVDV-Osloss (Renard et al., 1987; CoUett et al., 
1988a). 
The genomic organization of B VDV has been described (Collett et al., 1988a). The 
viral genome contains a single large open-reading frame (ORF) capable of encoding 3988 
amino acids or 449 kDa of protein (Collett et al., 1988a). The structure of the BVDV 
genome suggests that mature viral proteins are produced by co-transladonal and post-
translarional proteolytic processing of a polyprotein precursor. 
BVDV RNA represents a minor RNA species in virus-infected cells (Collett et al., 
1988a). RNA is isolated from gel electrophoresis as a single, high-molecular weight band 
that lacks a 3' poly A region. BVDV RNA is refractory to enzymatic poly A addition to the 
3' terminus by Escherichia coli polymerase (Renard et al., 1985; Collett et al., 1988a). T4 
RNA ligase is able to add cytidine 3', 5 -bisphosphate to the 3' end of BVDV RNA, 
indicating the presence of a 3' hydroxyl group (Renard et al., 1985). The 5' terminus of 
BVDV RNA is not labeled with 32p ATP when polynucleotide kinase is used, indicating the 
presence of a 5' cap (Collett et al., 1988a). Actinomycin D shuts down host cell RNA 
synthesis, but does not affect BVDV RNA replication (Horzinek, 1981; Purchio et al., 
1983), suggesting that the virus carries its own enzyme for RNA synthesis. 
BVDV RNA in infected cells appears to possess a high degree of secondary structure, 
based on observations that BVDV RNA must be denatured to serve as messenger for in vitro 
reticulocyte translation (Purchio et al., 1984) and exhibits resistance to low concentrations of 
RNase A (Purchio et al., 1983). The reported sedimentation values of between 24S and 
40S, with inactivity sedimenting at the higher values (Moennig, 1971; Purchio et al., 1983); 
solubility in 2 M LiCl (Collett et al., 1988a); and ability to bind to CF-11 cellulose in the 
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presence of 15% ethanol (Purchio et al., 1984), are all features found in replicative form 
RNA. However, sensitivity to higher concentrations of RNase A distinguishes BVDV RNA 
from true duplex (replicative form) RNA (Purchio et al., 1984). Replicative form or 
replicative intermediate RNA species of BVDV have not been described, but the secondary 
structure of BVDV RNA may prevent separation of genomic from replicative form or 
replicative intermediate RNA species. 
BVDV Proteins 
Early investigations of BVDV-specific polypeptides varied in the reported numbers 
and sizes of proteins. Disagreement was probably attributable to the relatively small amount 
of viral protein found in infected cells, and to the use of different analytical procedures. 
Pritchett and Zee (1975) detected four ^K-labeled BVDV proteins in infected cells. Coria et 
al. (1983) detected four major proteins, two of which were glycoproteins, by using 
coomassie-stained and dansyl-stained polyaciylamide gels. Purchio et al. (1984) found 
three major and two minor BVDV-specific proteins in virus-infected cell lysates by using 
radioimmuno-precipitation with convalescent bovine sera. Pocock et al. (1987) used 
gnotobiotic calf antisera to detect eight BVDV-specific polypeptides in cell lysates by 
radioimmuno-precipitadon. Donis and Dubovi (1987a, b) radiolabeled viral polypeptides in 
the presence of hypertonic translation initiation blockage, and immunoprecipitated twelve 
BVDV-specific proteins. Matthaeus (1979) observed the coprecipitation of host cell 
polypeptides with BVDV polypeptides, and described problems associated with the 
inefficient inhibition of host cell mRNA and protein synthesis by BVDV. 
Collett et al. (1988b) described the cloning of short segments of the BVDV genome 
as B-galactosidase fusion polypeptides in Escherichia coli. Sequence-specific antisera to 
these BVDV fusion proteins identified eleven BVDV proteins by immunoprecipitation. This 
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method accounted for 83% of the coding capacity of the virus genome. The order of BVDV 
encoded proteins on the genome was also determined. The genome order starting at the 5' 
end is: p20-gpl 16-pl25-p38-pl33. Several precursor-product relationships were suggested 
by the data. The precise positioning of BVDV proteins within the amino acid sequence is not 
yet known, however, the viral structural proteins appear to be clustered near the 5' end of the 
genome. 
The first protein of the ORF is a 20 kDa molecule rich in proline residues (11%). The 
estimated isoelectric point (pi) of this polypeptide is 10.6, and this is the highest of all BVDV 
proteins (Collett et al., 1988b). A glycoprotein region rich in cysteine residues (3.9%) 
follows. Viral glycoproteins were identified by immunoprecipitation of [^^S]methionine-
labeled BVDV-infected cell lysates (Collett et al., 1988b). The putative precursor, gpl 16, is 
processed to yield gp62, and gp53. Gp62 is further cleaved to give gp48 and gp25. 
Fourteen potential N-linked glycosylation sites (Asn-x-Ser/Thr) have been identified in the 
gpl 16 sequence (Collett et al., 1988b). Carbohydrate moieties on glycoproteins have been 
shown to have substantially different molecular weights, ranging from 512 daltons (Graham 
and Gottscholk, 1960) to 3400 daltons (Spiro, 1962). Variations in reported sizes of BVDV 
glycoproteins may be due to variations in amounts of bound sugar (Donis and Dubovi, 
1987b; Collett et al., 1988b). Partial or complete removal of carbohydrate by treatment with 
endoglycosidase increased the electrophoretic mobilities of the glycoproteins. Following 
enzymatic removal of N-linked glycans, gp53 had an estimated size of 42 kd (Collett et al., 
1988b). Tunicamycin blocks the addition of N-acetylglucosamine in the synthesis of N-
linked glycoproteins. Inhibition of assembly and maturation of other viruses following 
tunicamycin treatment has been reported (Leavitt et al., 1977), Virus infectivity can be 
affected following removal of carbohydrate moieties that may be involved in receptor 
recognition or virus entry (Pizer et al., 1980; Sahara et al., 1982). The addition of 
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tunicamycin to infected cells reduces the yield of infectious BVDV (Donis and Dubovi, 
1987b). 
Gp53 is consistently found in virus preparations and is an important antigen 
stimulating the bovine immune response to BVDV. Experimental data indicate that gp53 is 
an envelope glycoprotein. Neutralizing monoclonal antibodies recognize gp53 (Bolin et al., 
1988; Donis et al., 1988; Corapi and Dubovi, 1990). The mechanism of neutralization is not 
known, but may be due to interference with viral attachment to host cell receptors. 
The pl25/p54-p80 region encodes nonstructural viral proteins. The pl25 is present 
in both cytopathic and noncytopathic biotypes, whereas p80 is only produced in cytopathic 
BVDV isolates (Akkina, 1982; Donis and Dubovi, 1987b; Pocock et al., 1987). Purchio et 
al. (1984), using trypric peptide mapping techniques, determined that p80 was included 
within pl25. The function of the remaining viral proteins, pi33 and its cleavage products 
p7S and p58, has not been detennined. 
The identity of the BVDV nucleocapsid protein is not known. The p20 protein is a 
likely candidate for the nucleocapsid protein because it has a high isoelectric point (10.6), a 
high proline content, and is encoded within the genomic region suspected to include the viral 
structural proteins (Collett et al., 1988b). 
Antigenic Analysis 
Epitopes of proteins can be divided into two categories; sequence-dependent and 
conformadonally-dependent (Sela, 1969). Sequence-dependent epitopes are made up of a 
single, continuous length of the amino acid primary sequence. Conformadonally-dependent 
epitopes are comprised of amino acids that may be widely separated in the primary structure, 
but are brought in close proximity on the surface of the protein when the polypeptide chain is 
folded to form the structure of the native protein. 
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The term epitope has been applied to surface configurations, single determinants, 
immunogenic elements, haptenic groups, and antigenic patterns (Jeme 1960). Extrapolation 
studies with carbohydrate antigens have fostered the idea that protein epitopes are formed by 
hexapeptides. Current evidence indicates that epitopes on native proteins occupy large areas 
comprised of 15 - 22 amino acid residues in discontinuous array (Padlan et al., 1989; Tulip et 
al., 1989). 
Since their original description (Kohler and Milstein, 1975), monoclonal antibodies 
have been invaluable tools for investigating the antigenic relationships between viruses and 
viral proteins. The basic property of monoclonal antibodies, their recognition and specific 
binding to one epitope or family of related epitopes, may be used to provide information on 
structure, function, relatedness, synthesis and processing, and/or distribution. As illustrated 
by antigenic analysis performed with rabies virus (Hammand et al., 1980), minor differences 
between closely related proteins undetected by polyclonal sera may be readily evident by 
analyses with monoclonal antibodies. These minor antigenic differences, relevant in virus-
host interactions, are important in the development of vaccine programs for diseases caused 
by antigenically unstable viruses. 
Monoclonal antibodies may be tested for their cross reactivity with a panel of test 
antigens (viral isolates). The binding of antibodies in distinct reactivity patterns to a vital 
protein indicates the presence of distinct (operationally defined) epitopes on that protein 
(Yewdell and Gerhard, 1981). However, the topographic relationship between individual 
epitopes remains undefined. Three experimental approaches may be used to dissect the 
antigenic topology. First, the capacity of monoclonal antibodies to compete with each other 
for their individual epitopes on the viral protein can be determined. Second, the structural 
properties of the epitopes themselves can be assessed. Third, individual epitopes can be 
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grouped and arranged relative to each other by comparative analysis of antigenic variants 
selected for in the presence of monoclonal antibodies (Yewdell and Gerhard, 1981). 
Monoclonal antibodies were first used for antigenic analysis of togaviruses by 
Roehrig et al. (1980). Their application paralleled methods first introduced in studies with 
influenza virus (Webster and Laver, 1980) and murine ecotropic leukemia virus (Lostrum et 
al., 1979). The spatial orientation of epitopes recognized by a panel of monoclonal 
antibodies with respect to one another is defined in a competitive binding assay. Antibodies 
that mutually block each others binding recognize epitopes that are identical or closely 
associated spatially. Conversely, Heinz et al., (1984) working with several flaviviruses, 
demonstrated enhancement of binding by monoclonal antibodies recognizing spatially distant 
epitopes. 
Antigenic analysis of the immunologically important E2 glycoprotein of Venezuelan 
Equine Encephalitis (VEE) virus resulted in the identification of eight epitopes (Roehrig et 
al., 1982; Roehrig and Mathews, 1985). Similar studies with Semliki Forest virus (SFV) 
demonstrated the presence of five epitopes on the E2 glycoprotein (Boere et al., 1984). 
While polyclonal neutralizing antibodies are not produced against the togavirus El 
glycoprotein, analysis of VEE El glycoprotein with monoclonal antibodies identified four 
epitopes, one of which neutralized virus infectivity. The explanation for viral neutralization 
by a monoclonal antibody against the El glycoprotein was provided by the deduced spatial 
orientation of identified epitopes. The El-neutralizing epitope was in close proximity to the 
E2 glycoprotein in the togavirus E1-E2 glycoprotein dimer, indicating that steric hindrance of 
cell binding sites on the E2 occurred following binding of the monoclonal antibody to El. 
Sindbis virus and SFV were shown to have five and six epitopes respectively (Schmaljohn et 
al., 1983; Boere et al., 1984). Competitive binding assays with Western Equine 
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Encephalitis virus (WEE) revealed eight epitopes existed on the El glycoprotein (Hunt and 
Roehrig, 1985) 
A topographical model of epitopes on the structural glycoprotein E, for several 
flaviviruses, has been constructed. The most extensive analysis was performed with Tick-
Bome Encephalitis (TBE) virus. Guirakhoo et al. (1989) identified nineteen epitopes 
clustered in three non-overlapping antigenic domains. Reactivities of monoclonal antibodies 
and dieir affects upon functional activities associated with the E glycoprotein (Hemagglu-
tination-inhibition, neutralization, passive protection) were different (Heinz et al., 1983). 
Competitive binding assays have also been performed with Japanese Encephalitis (JE) virus 
(Kimura-Kuroda and Yasui, 1983,1984; Cecilia et al., 1988), Yellow Fever (YF) virus 
(Schlesinger et al., 1984; Cammack and Gould, 1986), and Dengue viruses (Henchal et al., 
1985). 
Diagnostic and (Quantitative Assays 
The earliest detection method for BVDV was direct inoculation of cattle (Olafson et 
al., 1946). A serum neutralization test, using animals, was first reported by Baker et al. 
(1954). This was followed by a serum neutralization test (SNT) in cell culture, using 
cytopathic BVDV (Gillespie et al., 1960). The phenomenon of interference of cytopathic 
viral isolates by noncytopathic BVDV provided a means of titration and identification without 
the necessity of animal inoculation (Gillespie et al., 1962). In cell cultures dually infected 
with both biotypes of BVDV, noncytopathic virus interferes with the production of CPE by 
the cytopathic isolate (Gillespie et al., 1962). CPE is characterized by vacuolation, 
rounding, and detachment of infected cells (Gillespie et al., 1960). Gutekunst and 
Malmquist (1964) used a modification of the interference test, and developed a neutralization 
test for noncytopathic BVDV isolates. Concurrently, Inaba et al. (1963) described an assay 
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for noncytopathic BVDV isolates that took advantage of the ability of B VDV to exalt 
Newcastle Disease virus (NDV) in cell culture. This procedure was termed the END method, 
for exaltation of Newcasde Disease Virus. 
Kniazeff and Pritchard (1960) reported using a cell culture plaque assay to conduct 
neutralization tests of various BVDV antisera against the Oregon C24 virus isolate. Later, 
Gatzek et al. (1967) published a more detailed description of a BVDV plaque assay. 
Darbyshire (1962), and Gutekunst and Malmquist (1963), used an agar gel diffusion assay to 
study the serological relationships between BVDV and other pestiviruses. 
Mengeling et al. (1963) first described an indirect fluorescent antibody test (IFA) in 
which conjugated anti-BVDV serum specifically stained bovine cells infected with BVDV. In 
1964, Femelius detected and titrated noncytopathic BVDV with fluorescein-conjugated 
antibody specific for either cytopathic of noncytopathic BVDV isolates. A complement-
fixation test (CF) for BVDV, using soluble antigen prepared from infected cell culture fluids, 
was reported by Gutekunst and Malmquist (1964). 
Enzyme-Linkgd Immunosorbent Assay (EUSA) 
Enzyme immunoassays originated with the work of Avrameas and Uriel (1966), who 
proposed labelling antigens and antibodies with enzymes for use in conventional serological 
techniques. Viral antigens in animal tissue sections were located by enzyme-labelled 
antibodies by Nakane and Pierce (1966), and Wincker and Avrameas (1969). Engvall and 
Perlmann (1971,1972) coined the term ELIS A to describe an assay comparable in sensitivity 
to radioimmunoassays. Polystyrene tubing was used as an immunosorbent support 
Subsequently, Voiler et al. (1974) developed an ELIS A by using polystyrene plates, 
and applied this method to the detection of antibodies to malaria (1974), rubella (1975), 
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measles, and cytomegalovirus (1976). In 1975, Ruitenberg et al. first applied the ELISA 
methodology to animal diseases, for the detection of antibodies to Trichinella spiralis. 
Advances in ELISA technology continued with togaviruses. Gravell et al. (1977) described 
the detection of antibodies to rubella virus. The detection of antibodies to the alphavirus 
VEE by ELISA was reported by Frazier and Shope (1979). This was followed by the 
application of ELISA to the detection of antibodies to flaviviruses: TBE (Hofmann et al., 
1979), and dengue virus (Dittmar et al., 1979). 
Chu et al. (1985) and Howard et al. (1985) reported the first ELISA for the detection 
of antibodies to BVDV. Liauw and Eugster, (1986) described an ELISA for the quantitation 
of immunoglobulin G to BVDV. Additional reports of indirect ELISA (Bock et al., 1986; 
Caquineau et al., 1986; Chu et al., 1987; Katz and Hanson, 1987) and blocking ELISA 
(Westenbrink et al., 1986; Katz and Hanson, 1987) for the detection of antibodies to BVDV 
have been made. Juntti et al. (1987) reported the use of monoclonal antibodies in indirect 
and competitive blocking ELISA to detect BVDV antibodies, and Justewicz et al. (1987) 
described a procedure using B VDV-infected cell monolayers for detection and quantitation of 
BVDV-specific antibodies. 
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SECTION I: EPITOPIC ANALYSIS OF TOE 53KD ENVELOPE 
GLYCOPROTEIN OF BOVINE VIRAL DIARRHEA VIRUS 
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ABSTRACT 
Thirteen monoclonal antibodies were prepared against five isolates of bovine viral 
diarrhea virus (BVDV). All of the antibodies reacted with viral protein gp53. In the absence 
of serum complement, each antibody neutralized infectivity of BVDV. The monoclonal 
antibodies were used in a competitive binding assay (CBA) to determine the topographic 
relationship of neutralizing epitopes on gpS3. Two distinct antigenic domains on the gp53 of 
cytopathic and noncytopathic isolates of BVDV were identified. The majority of monoclonal 
antibodies recognized overlapping epitopes in a single domain. A possible second domain 
was identified by the binding of one monoclonal antibody. A dot-immunoblot assay using 
denatured viral protein was performed. The results indicated that the neutralizing epitopes on 
gp 53 were conformationally-dependent. Endoglycosidase treatment of viral glycoproteins 
significantly reduced or prevented the binding of all thirteen monoclonal antibodies. 
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INTRODUCTION 
Bovine virai diarrhea virus (BVDV), an enveloped, single-stranded positive-sense 
RNA virus, is the type species of the Pestivirus genus in the family Toeaviridae (Mathews, 
1982; Westaway et al., 1985). Other members of the genus include hog cholera virus 
(HCV), and border disease virus of sheep (Horzinek, 1981), and all are closely related 
antigenically (Darbyshire, 1960,1962; Femelius et al., 1973; Osbum et al., 1973; Liess et 
al., 1977). BVDV is an economically important pathogen that induces a wide range of 
clinically mild to fatal diseases of cattle. There are two biotypes of BVDV which are 
differentiated by their ability to induce cytopathology in bovine cell cultures. Despite 
detectable biologic and molecular differences between both biotypes, detectable antigenic 
variation has been difficult to classify using conventional methods (Liess et al., 1977). 
Recent studies have indicated the potential of monoclonal antibodies (Mabs) to segregate 
isolates of BVDV into groups (Bolin et al., 1988). 
Molecular cloning of the BVDV genome has allowed a preliminary definition of the 
polypeptides encoded by the virus (Collett et al., 1988a, b). The identity of the BVDV 
glycoproteins was established by immunoprecipitation, using lysates of BVDV-infected cells 
labeled witii [^HJ mannose (Donis and Dubovi, 1987), [^H] glucosamine (Pocock et al., 
1987), and [^^S] methionine, followed by analysis of endoglycosidase-U'eated polypeptides 
(Collett et al., 1988b). The 53 kd glycoprotein of BVDV possesses epitopes to which virus-
neutralizing Mabs are directed (Bolin et al., 1988; Corapi et al., 1988; Donis et al., 1988; 
Magar et al., 1988). Previous studies have used reactivity patterns of large numbers of 
BVDV isolates with panels of Mabs to examine the antigenic nature and distribution of 
epitopes on the 53 kd glycoprotein (Bolin et al., 1988; Mateo Rosell, 1988; Moennig et al., 
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1989; Kreeft et al., 1990). While those studies indicated the presence of multiple epitopes on 
gp53, the topographic arrangement of those epitopes was not addressed. 
In this report, we describe the construction of topographic maps of epitopes on gp53 
of two BVDV isolates using competitive binding assays with radiolabeled Mabs. 
Furthermore, the dependence of these epitopes upon serum complement for virus 
neutralization was determined. And a preliminary examination of the position on the 
glycoprotein relative to carbohydrate moieties was made. 
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MATERIALS AND METHODS 
Monoclonal Antibodies 
All monoclonal antibodies used in this study have been previously described (Bolin et 
al., 1988) except for N2, BZ-2, and BZ-4, which were generated during this study in Dr. 
Bolin's laboratory. Balb/C or RBF/Dn mice (The Jackson Laboratory, Bar Harbor, ME) 
were immunized intraperitoneally or intrasplenically with concentrated and partially purified 
B VDV isolates, and hybridoma cells were produced by fusion of spleenic cells fiom 
immunized mice with Fox/NY (Taggart and Samloff, 1983) or SP2/0 /Agl4 myeloma cells 
as described by Peters et al. (1986). Screening for anti-BVDV Mab was performed by virus 
neutralization and immunohistochemical procedures, including indirect immunofluorescence 
assay (EFA), and immunoperoxidase assay (IP), (Ridpath et al., 1991). Antibody isotypes 
were determined by double immunodiffusion test using isotype-specific antisera (Litton 
Bionetics, Kensington, MD), and Mab specificity was established by immune precipitation of 
35s-labeled lysates of bovine turbinate (BT) cells infected with BVDV (Bolin et al., 1988). 
Hybridoma cells secreting anti-BVDV neutralizing Mab were grown in serum-free 
Dulbecco's MEM supplemented with AAT (7.5 x lO'^M adenine, 8 x lO'^M aminopterin 
and 1.6 X lO'^M thymidine). Cells were propagated either in suspension, or in cell culture 
flasks containing BT cell feeder layers. Supernatant from each hybridoma cell line was 
collected and stored at 4 C. Ascitic fluid for each Mab was produced in eight-week-old 
Balb/C mice primed with 0.5 milliliter of incomplete Freund's adjuvant. 
Purification and Labeling of Monoclonal Antibodies 
Mabs secreted from hybidomas grown in serum-free medium were precipitated with 
ammonium sulfate and dialyzed against .001M saline. Mabs were resuspended in phosphate 
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buffer (0.02M, pH 7.0) and applied to a protein G sepharose column (Pharmacia LKB, 
Uppsala, Sweden). The Mabs were eluted from the column with 0.1 M glycine-HCl (pH 
2.7). Fractions of eluate (1 ml) were collected and analyzed for protein content by 
absorbance at 280 nm UV light (Beckman DU-50 spectrophotometer, Beckman Instruments, 
Palo Alto CA). Fractions containing Mab were pooled, dialyzed overnight against 0.(X)1M 
phosphate buffer pH 7.0, and concentrated by lyophilization (Virtis Lyphilizer, Gardiner, 
NY). The lyophilized Mabs were resuspended in ddH20, and protein concentrations were 
determined. (Bio-Rad Protein Assay, Bio-Rad, Richmond, CA). 
Concentrated Mabs were labeled with Na-^^Sj using lodogen (1,3,4,6-tetrachloro-
3a,6a-diphenylglycoIuril, Pierce Chemical Co., Rockford, IL) by the method of Fraker and 
Speck (1978). The labeling reaction was stopped by gel filtration chromatography (Bio-gel 
P-10, Bio-Rad). One milliliter fractions were collected and their radioactivity quantitated (DP 
5500 Gammacounter, Beckman Instruments). Fractions were analyzed by SDS-PAGE in a 
discontinuous buffer system as described by Laemmli (1970). Gels were dried, and the 
presence of labeled heavy and light immunoglobulin chains was determined by 
autoradiography. Fractions containing labeled Mab were stored at -20 C. 
Vims, Cells, and BVDV Antigen Preparation 
The Singer isolate of cytopathic BVDV and the 7443 isolate of noncytopathic BVDV, 
were propagated in monolayers of BT cells as described previously (Ridpath et al., 1991). 
Cells infected with the cytopathic Singer virus were harvested when 90% of cells displayed 
cytopathic effect (18-22 hr post-infection). Cells infected with the noncytopathic 7443 virus 
were harvested 48 hr post-infection. 
Detergent solubilized antigen was prepared from BVDV-infected and uninfected BT 
cells scraped off three 150 cm^ cell culture flasks and solubilized using 13 mM of CHAPS 
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(3-[(3-cholami(iopropyl-diniethyl-ammonio]-l-propanesulfonate), Pierce) in phosphate 
buffered saline (PBS), pH 7.2 (2.5 ml/flask). Following a one hour incubation on ice with 
stirring, the mixture was sonicated (15 sec), and cell material was sedimented by 
centrifugadon for 15 minutes at 12,000 x g (Beckman eppendorf centrifuge, Beckman). 
Detergent was removed by overnight dialysis against O.OOIM phosphate buffer, pH 7.0, or 
by chromatography (Extracti-Gel-D column. Pierce). 
Complement-Dependence Assay 
Neutralization titers of anti-BVDV Mabs in the presence or absence of serum 
complement were measured. Complement-depleted fetal bovine sera was prepared by 
incubating one hour at 65 C before addition to F-15 Eagle's minimum essential media (MEM) 
(Grand Island Biological Co., GIBCO, Grand Island, NY, Gibco). BVDV-Singer and 
BVDV-7443 were propagated in complement-depleted MEM. Serial two-fold dilutions of 
Mabs were mixed 1:1 with virus lysate containing one hundred infectious particles and 
incubated for one hour at 37 C in 96-well microtiter plates (Costar, Cambridge, MA). 
Following addition of 10^ BT cells to each well, microtiter plates were incubated at 37 C for 
seventy-two hours and examined for viral neutralization using cytopathic eff^t or 
immunoperoxidase staining to detect virus. 
Antibody Binding Curves and Antibody Binding Constant Detennination 
The relative avidity for each labeled Mab was determined by coating and preparing 
polyvinyl chloride (PVC) 96-well microritration plates (Dynatech Industries, Chantilly VA) 
with solubilized BVDV antigen or uninfected BT-cell antigen, by the method of Frankel and 
Gerhard (1979). Antigen coated plates were incubated with blocking buffer (0.5% fish 
gelatin in PBS) (Saravis, 1984) for one hour at room temperature. Dilutions of labeled Mab 
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were added to microtitration plate wells and incubated three hours at room temperature. The 
microtitration plates were then washed six times each with TNE/W (0.5 M Tris-HCl, 0.15 M 
NaCl, 5 mM EDTA, pH 7.4,0.5% Tween-20), and ddHiO. Individual microtitration plate 
wells were cut out and the amount of bound labeled Mab was quantitated as before. Data 
were expressed as antigen-binding curves. Straight line regression analysis of the data was 
used to calculate antibody binding constants of each Mab (Frankel and Gerhard, 1979). 
Competitive Binding Assays (CBA) 
PVC microtiter plates were coated with solubilized BVDV antigen or uninfected BT 
cell antigen (0.1 ug/well), and prepared as before. Dilutions of labeled, purified Mabs, and 
nonlabeled competing Mabs (ascitic fluid) were made in TNE/W containing 0.1% fish 
gelatin. Labeled Mabs were diluted to the concentration at which 50% binding occurred as 
demonstrated in antibody binding curves, while nonlabeled competing Mabs (ascites fluid) 
were diluted ten-fold. Each CBA was performed using pairs of ^^^I-labeled and nonlabeled 
Mabs. Simultaneous and consecutive CBA's were performed to distinguish competition that 
may have been due to disparate antibody affinities. In simultaneous binding assays (one-
step), dilutions of labeled and nonlabeled competing Mab were mixed together, added to 
antigen-coated microtitration plate wells, and incubated three hours at room temperature. 
Each reaction was performed in triplicate. After incubation, the microtitration plates were 
washed six times each with TNE/W and ddHiO, individual wells were cut out, and the 
amount of bound labeled Mab was quantitated as before. In consecutive binding assays 
(two-step), dilutions of competing antibody were added to antigen-coated microtitration plate 
wells and incubated three hours at room temperature. The microtitration plates were then 
washed sbc times with TNE/W, labeled Mab was added to each well, and the plates incubated 
for three hours at room temperature. The microtitration plates were washed six times each 
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with first TNE/W, and then with ddH20. The microtitration plate wells were cut out and the 
amount of bound labeled Mab was quantitated as above. 
Reciprocal assays with pairs of Mabs were performed to identify compétition that 
may have been due to steric hindrance rather than true competition for epitopes. Reduction in 
binding of the labeled Mab by unlabeled antibody was calculated using the formula: 
1 - rftotal com - background cpm') - fcpm - background cpm^l x 100 
total cpm - background cpm 
and expressed in terms of percent competition. Competition between two Mabs for an 
epitope was indicated by a reduction of 60% or more in binding of the labeled antibody. 
Reduction of binding by 40 to 60% identified weak competition between pairs of Mabs. An 
increase of 50% or greater in binding of labeled Mabs identified enhancement of 
antibody binding. 
Endoglycosidase Treatment of Viral Antigen 
Detergent solubilized viral and uninfected cell protein were treated with Endo­
glycosidase H and F/N-glycosidase F (Boehringer-Mannheim Biochemicals, Indianapolis, 
IN) as described by Collett et al. (1988b). Enzyme treated and untreated protein mixtures 
were coated onto PVC microtitration plates wells and prepared as before. Labeled Mabs 
were added to the microtitration plate wells and incubated for three hours at room 
temperature. The microtitration plate wells were washed as above, cut out, and the amount 
of bound labeled Mab was quantitated as described. 
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RESULTS 
Labeling of Monoclonal Antibodies 
The procedures used to purify Mabs produced in serum-free media yielded about 50 
ug of Mab per 100 ml of cell culture supernatant Extraneous proteins were not detected by 
electrophoretic analysis of purified Mabs. Levels of incorporation of the varied among 
Mabs, regardless of the concentration of antibody used (table 1). lodination of Mabs CA 34, 
and CA 80, resulted in low levels of incorporation of radioactivity. Differences in labeling 
patterns of immunoglobulins were detected by autoradiography. Both heavy and light chains 
of all Mabs were labelled, except for CA 80 which incoiporated label in only the light chain. 
Antibody Avidity and Affinity Determination 
The relative avidity of each Mab for B VDV antigen was estimated from antigen 
binding curves in which antibody was titrated against constant amounts of bound antigen. 
The labeled Mabs were assayed against antigen from cytopathic BVDV-Singer and 
noncytopathic B VDV-7443 BVDV. Data were expressed in the form of antibody-binding 
curves that showed binding of each dilution of labeled Mab to bound BVDV antigen. The 
maximum level of binding (a measure of the relative avidity), and the Mab concentration at 
which 50% binding occurred, were determined. Figure 1 shows the antigen-binding curves 
for Mabs titrated against BVDV-Singer and BVDV-7443 antigen. The maximum level of 
binding (plateau level) varied among Mabs. 
Antibody binding constants for each Mab were calculated from regression analysis of 
data from the antigen-binding curves (table 2). Two Mabs, BZ>2 and BZ-4, had binding 
constants that were lower than the remainder of the panel by a factor of ten, while CA 36 had 
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the highest binding constant by a factor of ten. The remainder of the Mabs exhibited similar 
binding constants. 
Competitive Binding Assays (CBA) 
Twelve of thirteen Mabs bound epitopes on gp53 of the Singer isolate of virus (table 
2). Figure 2 shows the results of simultaneous competitive binding assays for neutralizing 
epitopes on gp53 of the Singer isolate between unlabeled competing Mabs and 125i_iabeled 
Mabs. Results of consecutive competitive binding assays were nearly identical (data not 
shown). Table 3 lists the results of each competitive binding assay perfoimed with the 
Singer isolate of cytopathic BVDV. 
Ten of thirteen Mabs bound epitopes on gp53 of noncytopathic BVDV-7443 (table 
2). Figure 3 shows the results of simultaneous competitive binding assays for neutralizing 
epitopes on gp53 of die 7443 isolate between unlabeled competing Mabs and ^^Sj.iabeled 
Mabs. Results of consecutive competitive binding assays were nearly identical (data not 
shown). Table 4 lists the results of each competitive binding assay performed with the 7443 
isolate of noncytopathic BVDV. 
Non-reciprocal enhancement of binding by ^^^I-labeled Mabs was observed in 
competitive binding assays with the 7443 isolate of noncytopathic BVDV. The binding of 
Mab CA 39 was enhanced by Mabs CA 34, CA 36, and N2, While the binding of antibodies 
CA 36, and N2 was enhanced by Mab CA 80. 
Potendal topographic maps of neutralizing epitopes on gp53 of the cytopathic Singer 
isolate and the nocytopathic 7443 isolate of BVDV defined by this panel are shown in figure 
4. Eleven Mabs reacted with overlapping epitopes in one antigenic domain on gp53 of the 
Singer isolate. A possible second antigenic domain was defined by CA 78, which did not 
compete with the other Mab. Nine of the ten Mabs recognized overlapping epitopes in one 
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antigenic domain on gp53 of the 7443 isolate. CA 24, which did not compete with the other 
Mabs defined a possible second antigenic domain. 
Further Characterization of GP53 Epitopes 
The neutralizing epitopes on gp53 were further characterized using a 
complement-dependence assay, and by antibody binding assays using endoglycosidase 
treated viral protein. Neither the presence or absence of complement affected viral 
neutralization by any Mab (table 5). Treatment of viral antigen with endoglycosidase H and 
F/N-glycosidase F greatly reduced or inhibited the binding of all thirteen Mabs (results not 
shown). 
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Table 1. Description of Monoclonal Antibody and Immunoglobulin 
Subclasses and Specific Activities After lodination. 
Monoclonal Fusion Isotype Immunogen^ Specific 
Antibody Partners Activity 
CAl rbf/dni -
FOX/NY2 
IgGl NADL 3.10 uCi/ug 
CA3 RBF/DN -Fox/NY IgGl NADL 2.58 uCi/ug 
CA24 RBF/DN-Fox/NY IgGl 7443 4.22 uCi/ug 
CA34 RBF/DN-Fox/NY IgG2a 7443 1.14 uCi/ug 
CA36 RBF/DN-Fox/NY IgG2b 7443 6.30 uCi/ug 
CA39 RBF/DN-Fox/NY IgGl Singer 2.69 uCi/ug 
CA72 RBF/DN-Fox/NY IgGl Singer 2.38 uCi/ug 
CA78 RBF/DN-Fox/NY IgG3 Singer 3.01 uCi/ug 
CA80 RBF/DN-Fox/NY IgGl Singer 1.35 uCi/ug 
CA82 RBF/DN-Fox/NY IgGl Singer 2.23 uci/ug 
N2 RBF/DN -Fox/NY IgGl Neb-Rkl3 3.59 uCi/ug 
BZ-2 Balb/C-SP2/0 IgG2b 88055 2.67 uCi/ug 
BZ-4 Balb/C-SP2/0 IgGl 88055 3.94 uCi/ug 
^ RB/DN mouse strain 
2 Fox/NY myeloma cell line 
3 Cytopathic viruses - Singer, NADL, 88055 
Noncytopathic viruses - 7443, Nebraska, Rkl3 
Figure 1: BVDV-Singer and BVDV-7443 antibody-binding curves. 
Dilutions of labeled, purified Mab were added to treated 
antigen coated PVC microtiter wells in triplicate, and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. Data was 
use to construct antibody-binding curves to determine 
relative avidity of each Mab. 
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Table 2. Binding Constants of Monoclonal Antibodies 
specific for BVDV. 
Monoclonal Antibody Binding Constant^ BVDV-Singer BVDV-7443 
CA 1 2.65 + .05 X 108M-1 +2 + 
CA 3 l.52±.07x I08M-1 + + 
CA24 5.57±.02x 108M-1 .3 + 
CA34 5.07 ±0.1 x 108m-1 + + 
CA36 8.30±.02x 108M-1 + + 
CA39 3.75+ .05 X 10%-! + + 
CA72 2.14±.09x 108M-1 + + 
CA78 2.60±.07x lO^M-l + -
CA80 2.43±.09x 108M-1 + + 
CA 82 5.73±.09x 108M-1 + + 
N2 3.63±.04x lO^M-l + + 
BZ 2 1.52 + .08X 108M-1 + -
BZ 4 2.23 + .02X 108M-1 + -
1 Determined by regression analysis of titration curves with the Singer isolate of cytopathic BVDV 
for all Mabs except CA 24. 
2 Binds to viral antigen 
3 Does not bind to viral andgen 
Figure 2: Simultaneous competitive binding assays of BVBV-Singer 
using Ca 1 and Ca 78. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing Mab 
(diluted ten-fold) were mixed and added to treated, antigen 
coated PVC microtiter wells in triplicate and incubated 3 hr at 
room temperature. Wells were washed six times each with 
TNE/W and ddHiO, cut out, and the amount of bound 
labeled Mab was quantitated. 
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Table 3: Simultaneous Competitive Binding Assays for BVDV-Singer 
Unlabeled Competing Monoclonal Antibody 
125i Cal Ca3 N2 Ca82 Ca36 Ca34 Ca39 Ca72 Ca80 BZ-2 BZ-4 Ca78 Ca24 
Mab 
Cal + + + + + + +/- + +/- - . . .  
Ca3 + + + -f- + + - + - - - - -
N2 + + • + + + + +nr - - + "h -
Ca82 + + + + + + + + - + 
Ca36 + + + + + + - + + - -
Ca34 + +/- + + + + - - +/- + + - -
Ca39 + +nr - + - - + + - -
Ca72 + + +nr + + +nr + + - + 
CaSO + +nr +nr +nr + + +nr +/-nr + - . . .  
BZ-2 - - + + +nr + +nr +/- - + 4" 
BZ-4 - - + + +nr + +/- +/- - + 
Ca78 - - - - - - - - - -
Ca24 
+ = > 60% competition 
+/- = 40-60% competition 
- = < 30% competition 
nr = non-reciprocal competition 
Figure 3; Simultaneous competitive binding assays of BVB V-7443 
using Ca 24 and Ca 80. Dilutions of labeled purifîed Mab 
(50% binding concentration) and noniabeled competing 
Mab (diluted ten-fold) were mbced and added to treated, 
andgen coated PVC microdter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Table 4: Simultaneous Competitive Binding Assay for BVD V-7443 
Unlabeled Competing Monoclonal Antibody 
125i Cal Ca3 N2 Ca34 Ca36 Ca72 Ca82 Ca80 Ca39 
Mab 
Ca 1 + + + + + + + +/- +/-
Ca3 + + + +/- + + + +/- +/-
N2 + + + + + + + Enr -
Ca34 + + + + + + + - +nr 
Ca36 + + + + + + + Enr +/-nr 
Ca72 + + + + + + + + + 
Ca82 + + + + + + + + + 
CaSO + + +nr +nr +nr + + + + 
Ca39 +/- +/- Enr Enr Enr + + + + 
Ca24 - - - - - - - - -
Ca78 -
BZ-2 - - - - - - - - -
BZ-4 
+ => 60% competition 
+/- = 40-60% competition 
- = < 30% competition 
nr = non-reciprocal competition 
E = enhancement of binding > 50% 
Figure 4: Proposed topographie maps of neutralizing epitopes on gp53 
of the Singer cytopathic and 7443 noncytopathic isolates of 
bovine vi^ diarrhea virus. 
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Table 5. Neutralization Titers of Monoclonal Antibodies specific for 
BVDV in the Presence and Absence of Serum Complement 
Monoclonal 
antibody 
Singer 
C'l No C 
7443 
C No C 
CA 1 10242 1024 512 512 
CA 3 1024 1024 512 512 
CA24 ND3 ND 64 32 
CA34 512 256 256 256 
CA36 32 16 256 256 
CA39 1024 1024 512 512 
CA72 <2 <2 512 512 
CA78 64 32 ND ND 
CA80 1024 1024 256 256 
CA82 1024 1024 512 256 
N2 1024 1024 1024 1024 
BZ 2 512 512 ND ND 
BZ 4 512 512 ND ND 
1 Serum complement 
^ Reciprocal of last dilution showing neutralization 
3 Not determined 
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DISCUSSION 
In this study, a panel of thirteen Mabs raised against gp53 of two cytopathic and four 
noncytopathic isolates of BVDV, that had viral neutralizing activity, were used in serological 
assays to characterize epitopes on the glycoprotein. Competitive binding assays between 
pairs of Mabs were performed to elucidate the topographical orientation. Antibody binding 
assays were used to estimate the relative avidity, and the affinity binding constant of each 
Mab was determined by regression analysis of the data. In addition, the position of these 
epitopes relative to carbohydrate moieties, was examined. 
Competitive binding assay results are based upon 1-step (simultaneous) assays 
(figures 2 and 3) which did not differ from 2-step (consecutive) assays. Non-reciprocal 
competition between antibody pairs was observed (table 3 and 4). Non-reciprocal 
competition is likely attributable to steric hinderance rather than specific binding of both Mabs 
to the epitope, therefore, these results were not used in construction of the topographical 
epitope maps. Potential topographic maps for the neutralizing epitopes on gp53 of the Singer 
cytopathic and 7443 noncytopathic isolates of BVDV are shown in figure 4. Most of the 
Mabs bound to a cluster of overlapping epitopes in a single antigenic domain (Domain A) on 
gp53 of both cytopathic and noncytopathic BVDV virus isolates. A possible second 
antigenic domain (Domain B) was identified on both cytopathic and noncytopathic BVDV 
isolates by binding of Mabs Ca 24 and Ca 78. Domain A on the Singer isolate was identified 
by the binding of eleven Mabs to overlapping epitopes, while eight Mabs bound to 
overlapping epitopes in domain A of the 7443 isolate. The difference in epitopic models for 
the cytopathic and noncytopathic BVDV isolates may be due in part to variability in epitopes 
on the gp53. Kreeft et al. (1990) have described rapid antigenic change in a BVDV vaccine 
virus and hypothesize the possibility of a virus mechanism that may cause epitopes to 
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disappear or emerge. There is a possibility that emergence of undetected epitopes may have 
altered the topography of the detected overlapping epitopes in domain A of both isolates. 
The influence of serum complement on neutralization of BVDV by this panel of 
Mabs, and further potential delineation of the epitopes recognized by the Mabs, was also 
examined by determining the neutralization titers of each Mab in the presence and absence of 
serum complement (table 5). The activation of the full complement cascade can effect 
irreversible damage to the envelope of a virus (Oldstone, 1975; Sissons and Oldstone, 1980). 
However, complement-effected lysis does not necessarily follow from complement 
activation. If antibody reacts with an epitope near the extremity of envelope proteins, the 
activated components of complement may lose their ability to bind before diffusing to the 
viral envelope. Secondly, complement-mediated damage may occur but fail to produce lysis 
if the density of epitopes on the virus is too low. The neutralization titer of each Mab in this 
panel was neither enhanced nor reduced, indicating that these epitopes were likely located 
near the free end of the viral glycoprotein. 
Endoglycosidase treatment of BVDV glycoproteins has been used to remove 
carbohydrate moieties from those proteins (Collett et al., 1988b). The topographical 
orientation of epitopes on the 53 kd glycoprotein was further analyzed by binding assays 
following treatment of viral glycoprotein with endoglycosidase H and F/N-glycosidase F. 
The binding of each antibody was either greatly reduced or prevented by the removal of 
carbohydrate from the glycoprotein (data not shown). These results might indicate that the 
neutralizing epitopes of BVDV are located in the portion of the glycoprotein that carries the 
carbohydrate moites. However, similar results with other viruses have lead to the hypothesis 
that removal of carbohydrate chains alters the three-dimensional structure of a protein, and 
may influence a distant antigenic site (Bruck et al., 1982). A procedure not done in this 
study that might provide additional information on the location of epitopes would be 
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propagation of B VDV in the presence of the n-iinked glycosylation inhibibitor, tunicamycin, 
and testing for binding by the Mab panel. 
Mateo Rosell (1988) and Moennig et al. (1989) have previously describe topographic 
analysis of BVDV gp53 epitopes, and determined the existence of at least four antigenic 
domains containing overlapping epitopes, using an immunoperoxidas assay. Our results of 
CBA's using radiolabeled Mabs extend the previous findings, and further reinforce the model 
of a limited number of neutralizing antigenic domains with overlapping epitopes. Qiaracter-
ization and topographical analysis of hog cholera vims epitopes (Wensvoort, 1989; 
Wensvoort et al., 1990; Greiser-Wilke et al., 1990) have also indicated the presence of at 
least three overlapping neutralizing antigenic domains. 
Antigenic analyses of proteins with Mabs is an important and useful tool. However, 
a finite panel of antibodies may only provide information about a limited number of epitopes. 
Proteins may carry a large number of antigenically reactive sites (Benjamin et al, 1984). 
However, Amon (1980) has suggested that only a limited number of potential antigenic sites 
are immunodominant and can stimulate a host's immune response. In tiiis study, domain A 
appears to be an immuno-dominant antigenic domain on gp53, but this may be a reflection of 
the panel of Mabs used. Mabs against BVDV are difficult to produce. This may be 
attributable to the difficulty in viral purification and/or immunogenicity of the viral proteins. 
The relatively limited number of Mabs available for this study may have influenced the 
results. The true, general antigenic structure of gp53 may only be assessed wiUi large, 
diverse panels of Mabs. 
In conclusion, the topographical orientation of neutralizing epitopes on the 53 kd 
envelope glycoprotein of BVDV was determined. At least two distinct antigenic domains 
were identified, made up of epitopes that are conformationally-dependent in nature. Virus 
neutralization at these epitopes is not complement-dependent. Furthermore, endoglycosidase 
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treatment indicates the epitopes appear to be located in or near the carbohydrate moieties of 
the glycoprotein. A high degree of antigenic mutation in BVDV has been observed. Results 
presented in this study are in accordance with those observations. 
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APPENDIX A: GRAPHS 
Figure 5: Simultaneous competitive binding assays of B VB V-Singer 
using Ca 1 and Ca 3. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 6: Simultaneous competitive binding assays of BVBV-Singer 
using Ca 24 and Ca 34. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC miciotiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
60 
Dilution of Unlabeled CA 24 
—a— CA1 
—•— CA3 
« CA24 
• CA34 
—•— CA 36 
0— CA 39 
CA72 
CA78 
CA 80 
CA 82 
—•— N2 
N BZ2 
• - H  BZ4 
D-
»-
CA1 
CA3 
CA24 
CA34 
CA36 
CA 39 
CA72 
CA78 
CABO 
CA 82 
N2 
BZ2 
BZ4 
Dilution of Unlabeled CA 34 
Figure 7: Simultaneous competitive binding assays of BVBV-Singer 
using Ca 36 and Ca 39. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
andgen coated PVC microdter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 8: Simultaneous competitive binding assays of BVBV-Singer 
using Ca 72 and Ca 78. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperanire. Wells were washed six 
times each with TNE/W and ddHiO, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 9: Simultaneous competitive binding assays of BVB V-Singer 
using Ca 80 and Ca 82. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 10: Simultaneous competitive binding assays of BVBV-Singer 
using N2 and BZ-2. Dilutions of labeled puriHed Mab (50% 
binding concen-ration) and nonlabeied competing Mab 
(diluted ten-fold) were mixed and added to treated, antigen 
coated PVC microtiter wells in triplicate and incubated 3 hr at 
room temperature. Wells were washed six times each with 
TNE/W and ddH20, cut out, and the amount of bound 
labeled Mab was quantitated. 
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Figure 11 : Simultaneous competitive binding assays of BVBV-Singer 
using BZ-4. Dilutions of labeled purified Mab (50% binding 
concentration) and nonlabeled competing Mab (diluted ten­
fold) were mixed and added to treated, andgen coated PVC 
microtiter weUs in triplicate and incubated 3 hr at room 
temperature. Wells were washed six times each with 
TNE/W and ddH20, cut out, and the amount of bound 
labeled Mab was quantitated. 
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Figure 12: Simultaneous competitive binding assays of BVBV-7443 
using Ca 1 and Ca 3. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated 
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Figure 13: Simultaneous competitive binding assays of BVBV-7443 
using Ca 24 and Ca 34. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 14; Simultaneous competitive binding assays of BVBV-7443 
using Ca 36 and Ca 39. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddHiO, cut out, and the 
amount of bound labeled Mab was quandtated. 
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Figure 15: Simultaneous competitive binding assays of BVBV-7443 
using Ca 72 and Ca 78. Dilutions of labeled purified Mab 
(50% binding concentradon) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 16: Simultaneous competitive binding assays of BVBV-7443 
using Ca 80 and Ca 82. Dilutions of labeled purified Mab 
(50% binding concentration) and nonlabeled competing 
Mab (diluted ten-fold) were mixed and added to treated, 
antigen coated PVC microtiter wells in triplicate and 
incubated 3 hr at room temperature. Wells were washed six 
times each with TNE/W and ddH20, cut out, and the 
amount of bound labeled Mab was quantitated. 
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Figure 17 : Simultaneous competitive binding assays of BVB V-7443 
using N2 and BZ-2. Dilutions of labeled purified Mab (50% 
binding concentration) and nonlabeled competing Mab 
(diluted ten-fold) were mixed and added to treated, antigen 
coated PVC microtiter wells in triplicate and incubated 3 hr at 
room temperature. Wells were washed six times each with 
TNE/W and ddH20, cut out, and the amount of bound 
labeled Mab was quantitated. 
82 
—m— 
• 
— — M— • 
CA1 
CA3 
CA24 
CA 34 
CA36 
CA 39 
CA72 
CA78 
CA80 
CA 82 
N2 
BZ2 
BZ4 
Dilution of Unlabeled N2 
-Q-
—  —  M — -
CA1 
CA3 
CA24 
GA34 
CA36 
CA 39 
CA 72 
CA78 
CA80 
CA82 
N2 
BZ2 
BZ4 
Dilution of Unlabeled BZ-2 
Figure 18: Simultaneous competitive binding assays of BVBV-7443 
using BZ-4. Dilutions of labeled purified Mab (50% binding 
concentration) and nonlabeled competing Mab (diluted ten­
fold) were mixed and added to treated, antigen coated PVC 
microtiter wells in triplicate and incubated 3 hr at room 
temperature. Wells were washed six times each with 
TNE/W and ddH20, cut out, and the amount of bound 
labeled Mab was quantitated. 
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APPENDIX B: MATERIALS 
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Serum Free Dulbecco's MEM 
Dulbecco's MEM (Grand Island Biological Co., Gibco, Grand Island, NY) supplemented to 10% 
with BVDV-frce fetal bovine serum, with the following added: 
Non-essential amino acids 25.0 ml/liter 
vitamin B12 0.625 mg/liter 
biotin 0.25 mg/liter 
sodium selenite 0.05 mg/liter 
insulin 5.0 mg/liter 
transferrin 5.0 mg/liter 
L-glutamine 50.0 mg/liter 
adenine 7.5 X 10-5M 
aminopterin 8 X 10-7M 
thymidine 1.6x10% 
Protein G sepharose Column buffer pH 7.0 
Na2HP04 
NaH2P04 
0.02M 
0.02M 
87 
Section D: NOVEL AND RAPED METHOD FOR PRODUCTION OF 
BOVINE VIRAL DIARRHEA VIRUS ANTIGEN 
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Summary. Bovine viral diarrhea virus (B VDV) antigen was produced by two methods of 
lysis and compared for use in enzyme immunoassays (EIA) for detection of antibodies 
against BVDV. In one method, B VDV antigen was purified from lysates of infected bovine 
turbinate (BT) cells using glycerol-potassium tartrate density gradients. In the second 
method, BVDV-infected BT cells were solubilized and viral antigen released using the 
zwitterionic detergent CHAPS. Detergent was removed by chromatography and antigen was 
ready for immediate use. The relative BVDV antigen yield was determined by EIA, and 
solubilized BVDV antigen could be detected at a sixteen-fold greater dilution than density 
gradient-purified viral protein. Detergent solubilized viral antigen was used in an EIA to 
detect antibody to BVDV in fetal bovine sera. BVDV antigen obtained from one 150 cm^ cell 
culture flask supplied sufficient antigen to assay 150 samples of fetal bovine serum. Results 
from the EIA correlated closely to those obtained using virus neutralization tests. 
Bovine viral diarrhea virus (BVDV) is a widespread and economically important viral 
pathogen of cattle. Serologic surveys indicate 60 to 90 percent of cattle in the United States 
have antibodies against BVDV (Kahrs et al., 1964; Bolin et al., 1985). The two biotypes of 
BVDV, noncytopathic and cytopathic, usually cause subclinical or mild disease (Malmquist, 
1968). Infection of pregnant dams is common, and frequently results in transplacental 
infection of the fetus. The outcome of fetal infection is influenced by gestational age (Orban 
et al., 1983; Liess et al., 1984; McCluricin et al., 1984). Infection during the first six months 
of pregnancy may result in fetal resorption, abortion, mummificadon, congenital defects, or 
the birth of weak, undersized calves (Kendrick, 1971; Brown et al., 1973; 1974; 1975). 
Fetuses infected during the last trimester arc able to mount an active immune response against 
BVDV (Brown et al., 1979). 
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Fetal bovine serum is widely used in cell culture because of its growth promoting 
capacity, low concentration of immunoglobulins, and availability. Antibody against B VDV 
in fetal bovine sera has been detected by several investigators (Kniazeff et al., 1967; Boone et 
al., 1972; and Rossi and Kiesel, 1974). When fetal calf serum contaminated with antibody 
against BVDV is included in medium used to propagate pestiviruses, the virus yield is 
reduced (Van Oirschot, 1983). Additionally, fetal bovine serum containing BVDV antibody 
would be undesirable for production of monoclonal antibodies by cell culture. 
Several microplate enzyme-linked immunosorbent assays (ELIS A) tests have been 
developed for detection of antibodies to BVDV in cattle sera. Two types of ELISA, 
competitve-blocking assays (Westenbrink et al., 1986; Junti et al., 1987; Katz and Hansen, 
1987), and indirect assays (Howard et al., 1985; Chu et al., 1985; Bock et al., 1986; Liauw 
and Eugster, 1986; Justewicz et al., 1987; Chu et al., 1987; Caquineau et al., 1988; Durham 
and Hassard, 1990) have been described. However, difficulties in working with BVDV 
including extensive antigen production procedures and low antigen yields limit the use of the 
ELISA. 
Monolayers of bovine turbinate (BT) cells were grown in 490 cm2 roller botties and 
150 cm2 cell culture flasks, using F-15 MEM (F-15 Minimum Essential Eagles Medium, 
Grand Island Biological Co. Grand Island, NY) supplemented with 10% fetal bovine sera. 
The fetal bovine sera was determined to be free of BVDV using viral isolation techniques, 
and free of antibodies against BVDV using viral neutralization and indirect immuno-
peroxidase staining procedures (Ridpath et al., 1991). BT cells grown in cell culture flasks 
and roller bottles were both infected with the Singer isolate of cytopathic virus as described 
elsewhere (McClurkin et al., 1974). 
Ten roller bottles of BT cells infected with the Singer isolate of cytopathic virus and 
ten roller bottles containing mock-infected BT cells were subjected to one freeze-thaw cycle. 
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Cells were removed and sonicated for 30 seconds. The preparations were centrifuged at 
8,000 X g for 45 minutes using a Type 19 rotor (Beckman Instruments, Palo Alto, CA) at 4 
C, and the supernatant was harvested. Viral and cell proteins were pelleted from the 
supematent by ultracentrifugation at 112,000 x g for 4 hours at 4 C in a SW 28 rotor 
(Beckman). Pelleted material was resuspended in minimal volumes of PBS (Dulbecco's 
phosphate buffered saline pH 7.2) and pooled. This material was layered onto 20% glycerol-
60% potassium tartrate (w/v in PNE 0.1 M Pipes, 0.1 M NaCl, 5mM EDTA pH 7.4) linear 
gradients and centrifuged at 242,000 x g for 16 hours at 4 C in a VTi 50 rotor (Beckman). 
One milliliter fractions were collected, dialyzed against 0.(X)1M phosphate buffer, and 
assayed for infective virus particles. Fractions containing infectious virus were pooled, 
pelleted by ultracentrifugation and resuspended in 100 ul of PBS. Mock-infected cellular 
protein was layered onto density-gradients, and fractionated. Fractions corresponding to 
virus-containing fractions were concentrated in the same nnanner. Protein concentrations 
were determined (Bio-Rad Protein Assay, Bio-Rad, Richmond, CA). 
Solubilized BVDV antigen and mock-infected cellular andgen was produced from 
three 150 cm^ cell culture flasks. Virus and cells were harvested when 90% of infected BT 
cell monolayers displayed cytopathic effects (vacuoladon). The infected cell monolayers and 
mock-infected cell controls were washed once with PBS, and scraped off cell culture flasks. 
The cells were resuspended in minimal volumes of PBS (2 mis/flask) and solubilized with 13 
mM CHAPS (3-[(3-cholamidopropyl)-dimethyl-ammonio]-l-propanesulfonate), Pierce 
Chemicals, Rockford, IL) for one hour on ice with stirring. Both preparations were 
sonicated (15 seconds), and cell material was sedimented by centrifugation for 15 minutes at 
12,000 X g (Beckman Eppendorf centrifuge, Beckman). CHAPS was removed from the 
solubilized cell material by chromatography (Extracd-Gel D detergent removal columns. 
Pierce) using PBS as column buffer. Detergent-solubilized BVDV antigen had a final 
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volume of 2 ml/flask. Protein concentrations of virus and mock-infected preparations were 
determined as before. 
Viral andgen prepared by either density-gradient purification or detergent 
solubilization was titrated. Two-fold serial dilutions of BVDV and uninfected BT-cell control 
antigen were made in TNE (0.05M Tris-HCL, 0.15M NaCl, 5mM EDTA) and coated onto 
96-well Polyvinyl chloride (PVC) microtitration plates (Dynatech Laboratories, Chantilly, 
VA) by drying overnight at 37 C. Following a 5 minute methanol fixation step (Frankel and 
Gerhard, 1979), microtitration plate wells were washed three times with 300 ul of TNE/W 
(0.05% Tween-20). The microtitration plates were drained, and blotted on absorbent paper. 
Nonspecific binding sites were blocked by adding 100 ul of blocking buffer (PBS, 0.5% fish 
gelatin, Sigma Chemicals, St. Louis, MO) (Saravis, 1984) in to each well, and the plates 
were then incubated one hour at room temperature. Plates were washed once with TNE/W, 
and antibody-positive bovine serum diluted 1:100 in ELISA buffer (TNE, 2.0% Tween-20, 
0.5% fish gelatin, 0.78M NaCl, 80 U/ml heparin) was added to all microtitration plate wells. 
Following a 30 minute incubation at 4 C, microtitration plate wells were washed 5 times with 
TNE/W, and 50 ul of protein G-peroxidase conjugate (Zymed Laboratories, San Francisco, 
CA) diluted 1:8000 in PBS was added to each well for a 30 minute incubation at 4 C. 
Microtitration plates were washed five times with TNE/W, and 100 ul of ABTS (Kirkegaard 
and Perry, Gaithersburg, MD) was added to each well and incubated at room temperature. 
The reaction was stopped by addition of 50 ul of a 1:4(X) dilution of HF (hydrogen fluoride) 
to each well, and the optical density (OD) at 410 nm of each well was determined using an 
ELISA reader (Dynatech). 
Each test consisted of a three well series; one preabsorbtion well, one negative control 
well, and one test well. Initially, 50 ul of a 450 ug/ml uninfected cell antigen suspension was 
added to each preabsorbtion and control well, and 50 ul of an equal concentration of viral 
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antigen was added to each test well. After an overnight incubation at 37 C, the dried wells 
were fixed with methanol for 5 minutes, then washed three times with TNE/W. Next, 100 ul 
of blocking buffer was added to each well and incubated one hour at room temperature. 
Plates were washed once with TNE/W, and 20 ul of undiluted fetal bovine serum was added 
to the prcabsorbtion wells. After a one hour incubation at room temperature, 5 ul of pre-
absorbed fetal bovine serum was transfered to control and test wells, and 45 ul of ELIS A 
buffer was added. The microtitration plates were incubated 30 minutes at 4 C, and then 
washed five times with TNE/W. Next, 50 ul of Protein G-Peroxidase conjugate (Zymed) 
diluted 1:8000 in PBS was added to each well, and the plates were incubated 30 minutes at 4 
C. Microtitration plates were washed five times with TNE/W, and 100 ul of ABTS 
(Kirkegaard and Perry) was added to each well and incubated at room temperature for 30 
minutes. The reaction was stopped as before, and the optical density (OD) at 410 nm of each 
microdtradon plate well was obtained. Data were analyzed using the Softmax ELISA 
program (Molecular Devices, Menlo Park, CA). The reactivity of the fetal bovine sera was 
expressed in EIA units defined as; 
(OD of test wein - fOD of cell control wein x 100 
(mean net OD of positive control) - (mean net OD of negative control) 
Fetal bovine sera that were positive (82 samples) or negative (209 samples) for virus 
neutraliâng antibodies by immunoperoxidase staining as described elsewhere (Ridpath et al., 
1991), and virus neutralization test (Carbrey et al., 1974), were collected and stored at -20 C. 
The samples of sera were from pools of serum obtained from two to three fetuses. 
Positive control serum was obtained from a cow vaccinated with modified-Iive virus 
vaccine. Negative control serum was obtained from a cow that lacked detectable antibodies 
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against BVDV using radioimmunoprecipitation, serum neutralization, and indirect 
immunoperoxidase staining. 
Ten roller bottles of BVDV-infected BT cells yielded 0.4 ng of protein, from pooled 
and pelleted fractions of glycerol-potassium tarti-ate gradients, as measured by protein assay. 
Each 150 cm^ cell culture flask solubilized with CHAPS detergent yielded an average of 1.2 
mg of a mixture of viral and BT cell protein. When titrated against bovine serum containing 
antibody against BVDV in an ELA, density-gradient purified viral protein was not detected 
beyond the 1:4 dilution. In the detergent-solubilized infected cell lysate, viral antigen was 
titrated to the 1:64 dilution. 
Detergent-solubilized viral antigen and uninfected BT cell antigen were coated onto 
microtiter plates and used in an EIA to detect antibodies against BVDV in fetal bovine semm. 
Reactivity of the fetal bovine serum was expressed in EIA units. Results are listed in table 1. 
A value of ten EIA units was chosen as the cut-off between positive and negative results. Of 
82 viral neutralization positive samples of fetal bovine serum, the ELIS A identified 10 as 
negative. Of these 10 serum lots, 5 had a viral neutralization titer of 2. A total of 200 viral 
neutralization negative lots were tested by EIA, and 6 tested positive. The EIA in this study 
had a relative sensitivity of 87.8%, and a relative specificity of 97.0%. 
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Table 1. Comparison of enzyme immunoassay with serum neutralization 
for detection of anti-B VDV antibodies. 
EIA result Serum neutralization test result 
Positive^ Negative 
Positive^ 72 (a) 6 (b) 
Negative 10 (c) 194 (d) 
1 Titer equal to or greater than 1/2 
2 Activity in ELISA units greater than 10 
Relative sensitivity (a/a+c)=87.8% 
Relative specificity (d/b+d)=97.G% 
Predictive value (a/a+b)+92.3% 
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This study presents a novel and rapid method for producdon of BVDV antigen for 
use in an EIA. Previously described methods for BVDV antigen production involved 
multiple centrifugation steps and purification through sucrose or glycerol-potassium tartrate 
density gradients (Chu et al., 1987; Magar and Lecomte, 1987). Such purification 
procedures cannot be completed rapidly, and the end result is a low yield of BVDV antigen. 
In this study, infected monolayers of BT cells were solubilized with the zwitterionic 
detergent CHAPS to release native virus particles and viral proteins. This method of antigen 
production is much more rapid than density-gradient purification. Preparation of detergent-
solubilized BVDV antigen is completed less than 24 hours following infection of cell 
monolayers, while at least six days arc necessary to produce density-gradient purified BVDV 
antigen. In addition, rather than propagating BVDV in roller botties in order to maximize 
antigen yield, cell culture flasks are used, eliminating much of the media and supplies 
necessary for BVDV antigen production. Since volumes during each step of the procedure 
were purposely kept low, density-gradients were not needed, nor were multiple 
centrifugation steps and pelleting of virus necessary. This eliminated most of the steps 
during which the antigen could be lost or denatured. Following detergent removal by 
chromatography, virus protein suspensions were ready for immediate use in an EIA. 
Although equal starting concentrations of antigen were used and diluted identically, the 
detergent-solubilized BVDV antigen could be diluted sixteen times further than gradient 
purified viral antigen. Repeated manipulations during the production of gradient purified 
BVDV antigen probably contributed to the low yield. In addition, since BVDV forms broad 
bands in density gradients, fractions containing BVDV protein can only be identified with 
assays that detect infectious virus particles. Any disrupted virus or viral proteins would be 
lost and unavailable for immunoassays. 
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The choice of a suitable detergent for purification of membrane proteins is usually 
based upon the ability of the detergent to preserve native properties of the protein, especially 
important is antigenicity. Detergents can be denaturing or nondenaturing. Anionic detergents 
such as sodium dodecyl sulfate (SDS) or cationic detergents completely disrupt membranes 
and denature proteins. Nondenaturing detergents can be divided into nonionic detergents 
such as Triton X-lOO, and zwitterionic detergents such as CHAPS (Bitonti et al., 1982; 
Crawford et al., 1984; Mukhlis et al., 1986). Two other important considerations when 
choosing a solubilizing agent are, the degree of artifactual aggregation to form nonspecific 
protein complexes, and ease of removal of the detergent from solubilized proteins. Nonionic 
detergents are not efficient at disaggregating solubilized proteins, while zwitterionic 
detergents are efficient at disrupting protein-protein interactions, and have a high CMC 
(critical micelle concentration) which allows the detergent to be removed easily by dialysis. 
Previous studies have already described the release of viral glycoproteins via zwitterionic 
solubilization (Crawford et al., 1984). 
Detection of antibodies to BVDV in fetal bovine serum is currentiy performed by 
indirect fluorescent antibody tests, immunoperoxidase staining, or by serum neutralization 
tests. Each assay is not without its disadvantages, such as nonspecificity, ambiguous 
results, and the time necessary to set up and perform the assays. ELISA's have been adapted 
for use with BVDV to detect antibodies to BVDV in cattle sera, but these assays require 
extensive antigen production protocols (Howard et al., 1985; Chu et al., 1985; Katz and 
Hanson, 1987). The antigen production method introduced here is fast and simple. Whereas 
purification procedures would involve as many as six days (from infection of cell cultures to 
coating of microtiter plates) to prepare BVDV antigen, detergent solubilized BVDV antigen is 
available less than twenty-four hours. This study has demonstrated that more 
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immunologically recognizable BVDV antigen can be produced by zwitterionic detergent 
solubilization in a shorter time than density gradient purification. 
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GENERAL DISCUSSION AND SUMMARY 
The first study utilized a panel of thirteen monoclonal antibodies to characterize the 
neutraliàng epitopes on the 53 kd glycoprotein of BVDV. The physical nature of the 
epitopes, the relationship of these epitopes to serum complement, and their position on the 
glycoprotein relative to carbohydrate moieties, was examined In addition, the topographic 
orientation of the epitopes on the envelope glycoprotein was determined by competitive 
binding analysis with the panel of monoclonal antibodies. Competition between pairs of 
antibodies may indicate the antibodies belong to the same binding group, i.e. recognize the 
same epitope. However, several factors may explain apparent competition between two 
antibodies. First, the physical bulk of a monoclonal antibody bound to an epitope may 
sterically hinder the binding of another antibody to a separate and distinct epitope. Secondly, 
the binding of one monoclonal antibody at a distinct epitope may induce a conformational 
change in the protein, masking the epitope of another antibody. Third, the labeling of a 
monoclonal antibody may alter its ability to bind to its specific epitope (Yewdell and Gerhard, 
1981). Conversely, while failure of competition provides evidence that the antibodies bind to 
distinct sites on the antigen, antibodies will not compete with each other for the same epitope 
if they possess significantly different affinities for the epitope. 
Data suggest the epitope recognized by each monoclonal antibody was 
conformationally-dependent, or was a discontinuous epitope formed by amino acid residues 
that were not contiguous in the primary sequence. The neutralization titers of each 
monoclonal antibody in the presence and absence of serum complement, gave an indication 
of the relative position of epitopes on the viral glycoprotein. Since none of tiie monoclonal 
antibodies was dependent upon the presence of serum complement for neutralization, the 
epitope for each antibody may be located at the distal end of the glycoprotein, away from the 
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surface of viral envelope. These results correlate with those determined following 
endoglycosidase treatment of the viral glycoprotein. Treatment of BVDV glycoproteins 
indicated that the neutralizing epitopes on gp 53 of BVDV were either located in the portion 
of the glycoprotein that carried the carbohydrate moieties, or were in close proximity to this 
region. The removal of the carbohydrate moieties likely altered the conformation of the 
glycoprotein epitopes in that region, and affected the binding of antibodies. 
Two potential antigenic domains were identified on the BVDV glycoprotein. Eleven 
of the monoclonal antibodies bound to overlapping epitopes in one antigenic domain, while 
another domain was recognized by two monoclonal antibodies, Ca 24 and Ca 78. However, 
since this study did not use an isolate to which both Ca 24 and 78 bound, their epitopes could 
not be distinguished. 
Van Drunen et al. (1985) determined that the extent of blocking in a competitive 
binding assay is directly proportional to the avidity of each monoclonal antibody. The 
relative avidity of each monoclonal andbody was determined for both isolates of BVDV used 
in this study. This was used to estimate the amount of labeled antibody necessary for each 
assay. The binding constant of each monoclonal antibody was also determined, since this 
would provide more infomiation on whether any competition between two antibodies was 
true competition or an artifact of differences in binding strength. The binding constants for 
three monoclonal antibodies in this panel (table 2) varied significantly from the others. But 
the remainder of the panel had similar binding strengths. 
The second study described a novel and rapid protocol for BVDV antigen production 
using the zwitterionic detergent CHAPS to solubilize infected cell monolayers and obtain 
antigen without the need for time-consuming purification steps. The study compared the ease 
of density gradient purification and detergent solubilization, as well as the yield of viral 
antigen from the two methods, and determined that a greater amount of BVDV antigen could 
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be obtained in less time than the standard antigen purification procedure. While density-
gradient purification procedures would involve as many as six days to prepare B VDV 
antigen, detergent-solubilized BVDV antigen is available less than twenty-four hours 
following infection. Use of the zwitterionic detergent CHAPS ensured that protein was not 
denatured as could be the case when anionic detergents are used for solubilization. Detergent 
could be rapidly removed from protein suspensions by chromatography, or removed by 
overnight dialysis. Most of the contaminating cell protein was removed by a centrifugation 
step, and the viral antigen was ready for immediate use. 
The utility of the viral antigen was tested in an enzyme immunoassay. Fetal bovine 
sera was assayed for presence of antibody against BVDV, and results were compared to 
those determined by a viral neutralization test. This enzyme immunoassay used several steps 
to reduce inherent high background associated with BVDV serological assays. Some inert 
blocking proteins commonly used used to prevent nonspecific binding by antibodies (bovine 
serum albumen, and skim milk) are not acceptable due to the potential presence of BVDV 
antibody. This difficulty was overcome by using a fish gelatin blocking agent (Saravis, 
1984). Fish gelatin should be an immunologically unfamiliar protein to cattle, with little 
likelihood that the bovine immune system would produce antibodies to it. A methanol 
fixation step (Frankel and Gerhard, 1979), a buffer that contained high salt and Tween-20 
concentrations, and heparin (Dietzgen and Francki, 1987), each contributed to a reduction in 
non-specific background. Heparin is a cationic protein that binds to highly anionic 
molecules, i.e. proteins or antibodies, and also prevents nonspecific binding. In addition, 
the protein G-peroxidase conjugate eliminated the need for a second antibody species, and 
may also have helped to reduce the nonspecific background. A high correlation between the 
enzyme immunoassay and virus neutralization test was seen. This study presents a rapid 
method for generation of BVDV antigen that can be used for easy detection of BVDV 
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antibodies in fetal bovine serum, and can be adapted to detection of B VDV antibodies in 
vaccinated animals. 
In conclusion, the work presented here described the antigenic characterization of the 
53 kd envelope glycoprotein of BVDV, and a novel and rapid method for production of 
BVDV andgen using a zwitterionic detergent, that can be used in enzyme immunoassays as 
well as the competitive binding assays described in the fîrst study. 
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